Form 4 for TRAW Traws Pharma, Inc.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0000929638-24-001362 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-03 | 2024-04-01 | TRAW | CAUTREELS WERNER | CEO, Dir | A - Grant | — | +200.0K | 200.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-01 | A | A | 200,000 | — | 200,000 | D | — | — | (F1) Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis. |